Alpha-synucleinopathies are prevalent neurological disorders that cause significant disability, leading to progressive clinical deterioration that is currently managed solely through symptomatic treatment. Efforts to evaluate disease-modifying therapies during the established stage of the disease have not yielded positive outcomes in terms of...
-
2024 (v1)PublicationUploaded on: September 12, 2024
-
2024 (v1)Publication
Background: Currently, no standard scale has been validated to assess overall severity of RBD symptoms in the home environment. We aimed to evaluate the psychometric properties of the International RBD Severity Scale (IRBD-SSS), a new tool designed by the International RBD Study Group. Methods: Two versions of the IRBD-SSS were created, one for...
Uploaded on: October 16, 2024